AWM
BCLI

Avior Wealth Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Avior Wealth Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-747
Closed -$1.7K – 886
2024
Q4 		$1.7K Sell
747
-2
-0.3% -$4 ﹤0.01% 2142
2024
Q3 		$2.59K Hold
749
– – ﹤0.01% 1934
2024
Q2 		$3.8K Sell
749
-97
-11% -$727 ﹤0.01% 1805
2024
Q1 		$7.16K Hold
846
– – ﹤0.01% 1970
2023
Q4 		$3.46K Hold
846
– – ﹤0.01% 1243
2023
Q3 		$2.54K Hold
846
– – ﹤0.01% 1357
2023
Q2 		$26.1K Hold
846
– – ﹤0.01% 890
2023
Q1 		$41.9K Buy
+846
New +$24.5K ﹤0.01% 816

Other funds holding BCLI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Avior Wealth Management's BCLI Position: Q1 2025 in Review

Avior Wealth Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2025, closing a stake of 747 shares — an estimated $1.7K sold.

Avior Wealth Management first reported a position in BCLI in Q1 2023 and held it in 8 quarters. The position peaked at $41.9K in Q1 2023. 32 funds tracked by Wall St. Rank hold BCLI as of Q1 2025.

  • Avior Wealth Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2025 after selling out during the quarter.
  • Avior Wealth Management sold 747 BRAINSTORM CELL THERAPUTC shares in Q1 2025, an estimated $1.7K.
  • Avior Wealth Management first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2023 and held it in 8 quarters.
  • Avior Wealth Management's BRAINSTORM CELL THERAPUTC position peaked at $41.9K in Q1 2023.
  • 32 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2025.

Based on Avior Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.